Literature DB >> 11916905

Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells.

Deborah M Muoio1, James M Way, Charles J Tanner, Deborah A Winegar, Steven A Kliewer, Joseph A Houmard, William E Kraus, G Lynis Dohm.   

Abstract

In humans, skeletal muscle is a major site of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) expression, but its function in this tissue is unclear. We investigated the role of hPPAR-alpha in regulating muscle lipid utilization by studying the effects of a highly selective PPAR-alpha agonist, GW7647, on [(14)C]oleate metabolism and gene expression in primary human skeletal muscle cells. Robust induction of PPAR-alpha protein expression occurred during muscle cell differentiation and corresponded with differentiation-dependent increases in oleate oxidation. In mature myotubes, 48-h treatment with 10-1,000 nmol/l GW7647 increased oleate oxidation dose-dependently, up to threefold. Additionally, GW7647 decreased oleate esterification into myotube triacylglycerol (TAG), up to 45%. This effect was not abolished by etomoxir, a potent inhibitor of beta-oxidation, indicating that PPAR-alpha-mediated TAG depletion does not depend on reciprocal changes in fatty acid catabolism. Consistent with its metabolic actions, GW7647 induced mRNA expression of mitochondrial enzymes that promote fatty acid catabolism; carnitine palmityltransferase 1 and malonyl-CoA decarboxylase increased approximately 2-fold, whereas pyruvate dehydrogenase kinase 4 increased 45-fold. Expression of several genes that regulate glycerolipid synthesis was not changed by GW7647 treatment, implicating involvement of other targets to explain the TAG-depleting effect of the compound. These results demonstrate a role for hPPAR-alpha in regulating muscle lipid homeostasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916905     DOI: 10.2337/diabetes.51.4.901

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  84 in total

1.  HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

Authors:  Scott R Richmond; Michael J Carper; Xiaoyong Lei; Sheng Zhang; Kevin E Yarasheski; Sasanka Ramanadham
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 2.  Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport.

Authors:  C Fürnsinn; T M Willson; B Brunmair
Journal:  Diabetologia       Date:  2006-11-22       Impact factor: 10.122

3.  The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.

Authors:  Tsuyoshi Goto; Mariko Hirata; Yumeko Aoki; Mari Iwase; Haruya Takahashi; Minji Kim; Yongjia Li; Huei-Fen Jheng; Wataru Nomura; Nobuyuki Takahashi; Chu-Sook Kim; Rina Yu; Shigeto Seno; Hideo Matsuda; Megumi Aizawa-Abe; Ken Ebihara; Nobuyuki Itoh; Teruo Kawada
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

4.  Phytochemical composition and metabolic performance-enhancing activity of dietary berries traditionally used by Native North Americans.

Authors:  Tristan F Burns Kraft; Moul Dey; Randy B Rogers; David M Ribnicky; David M Gipp; William T Cefalu; Ilya Raskin; Mary Ann Lila
Journal:  J Agric Food Chem       Date:  2008-01-23       Impact factor: 5.279

5.  Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier.

Authors:  M Grabacka; P Waligorski; A Zapata; D A Blake; D Wyczechowska; A Wilk; M Rutkowska; H Vashistha; R Ayyala; T Ponnusamy; V T John; F Culicchia; A Wisniewska-Becker; K Reiss
Journal:  J Physiol Pharmacol       Date:  2015-04       Impact factor: 3.011

6.  Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals.

Authors:  Leslie A Consitt; Jill A Bell; Timothy R Koves; Deborah M Muoio; Matthew W Hulver; Kimberly R Haynie; G Lynis Dohm; Joseph A Houmard
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

Review 7.  Muscle as a "mediator" of systemic metabolism.

Authors:  Kedryn K Baskin; Benjamin R Winders; Eric N Olson
Journal:  Cell Metab       Date:  2015-02-03       Impact factor: 27.287

Review 8.  Clocking In, Working Out: Circadian Regulation of Exercise Physiology.

Authors:  Drew Duglan; Katja A Lamia
Journal:  Trends Endocrinol Metab       Date:  2019-05-02       Impact factor: 12.015

9.  Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids.

Authors:  Paul S Phillips; Theodore P Ciaraldi; Dong-Lim Kim; M Anthony Verity; Tanya Wolfson; Robert R Henry
Journal:  Endocrine       Date:  2008-12-03       Impact factor: 3.633

10.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.